Lombard Odier Asset Management Switzerland SA Takes $1.10 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY

Lombard Odier Asset Management Switzerland SA bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 3,320 shares of the biopharmaceutical company’s stock, valued at approximately $1,098,000.

Several other hedge funds have also made changes to their positions in the company. Waverly Advisors LLC raised its position in shares of Alnylam Pharmaceuticals by 8.0% during the 1st quarter. Waverly Advisors LLC now owns 907 shares of the biopharmaceutical company’s stock valued at $300,000 after buying an additional 67 shares during the period. Wealth Alliance LLC acquired a new position in Alnylam Pharmaceuticals in the first quarter valued at approximately $336,000. Entropy Technologies LP grew its position in Alnylam Pharmaceuticals by 121.9% in the first quarter. Entropy Technologies LP now owns 35,719 shares of the biopharmaceutical company’s stock worth $11,818,000 after acquiring an additional 19,622 shares during the period. Modern Wealth Management LLC purchased a new position in Alnylam Pharmaceuticals in the first quarter worth approximately $229,000. Finally, Bank of Nova Scotia increased its stake in Alnylam Pharmaceuticals by 0.6% during the first quarter. Bank of Nova Scotia now owns 7,798 shares of the biopharmaceutical company’s stock worth $2,580,000 after acquiring an additional 49 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Morgan Stanley lifted their target price on Alnylam Pharmaceuticals from $370.00 to $400.00 and gave the company an “equal weight” rating in a research report on Friday, July 10th. Truist Financial lowered their price target on Alnylam Pharmaceuticals from $505.00 to $410.00 and set a “buy” rating for the company in a report on Monday, July 13th. Royal Bank Of Canada cut their price objective on Alnylam Pharmaceuticals from $450.00 to $445.00 and set an “outperform” rating for the company in a research report on Friday, May 1st. Citigroup assumed coverage on shares of Alnylam Pharmaceuticals in a report on Tuesday, May 19th. They issued a “buy” rating and a $380.00 price objective on the stock. Finally, HC Wainwright upped their target price on shares of Alnylam Pharmaceuticals from $470.00 to $485.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $452.13.

Alnylam Pharmaceuticals Stock Up 2.4%

Shares of NASDAQ ALNY opened at $278.40 on Tuesday. The firm has a market cap of $37.17 billion, a price-to-earnings ratio of 76.07 and a beta of 0.27. The company has a quick ratio of 3.06, a current ratio of 3.13 and a debt-to-equity ratio of 0.94. Alnylam Pharmaceuticals, Inc. has a 52-week low of $262.21 and a 52-week high of $495.55. The business’s 50 day moving average is $292.06 and its two-hundred day moving average is $315.16.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, topping analysts’ consensus estimates of $0.87 by $1.12. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The company had revenue of $1.17 billion for the quarter, compared to analysts’ expectations of $1.12 billion. During the same period in the prior year, the firm earned ($0.44) earnings per share. The firm’s revenue was up 96.4% compared to the same quarter last year. Research analysts predict that Alnylam Pharmaceuticals, Inc. will post 7.35 EPS for the current year.

Insider Activity

In related news, Director David E. I. Pyott sold 3,830 shares of the stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the transaction, the director owned 1,582 shares of the company’s stock, valued at approximately $473,302.76. This represents a 70.77% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.